Laurent Goux - Krystal Biotech Senior Europe
KRYS Stock | USD 164.10 0.32 0.20% |
Executive
Laurent Goux is Senior Europe of Krystal Biotech
Address | 2100 Wharton Street, Pittsburgh, PA, United States, 15203 |
Phone | 412 586 5830 |
Web | https://www.krystalbio.com |
Krystal Biotech Management Efficiency
The company has return on total asset (ROA) of (0.0497) % which means that it has lost $0.0497 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0887 %, meaning that it created $0.0887 on every $100 dollars invested by stockholders. Krystal Biotech's management efficiency ratios could be used to measure how well Krystal Biotech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Krystal Biotech's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.13) in 2024. At this time, Krystal Biotech's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 630.6 M in 2024, whereas Other Assets are likely to drop slightly above 354 K in 2024.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Bradley CPA | GCM Grosvenor | N/A | |
Yaron Aharon | Nayax | N/A | |
John Davis | GCM Grosvenor | N/A | |
Leila Arsan | GCM Grosvenor | N/A | |
Harvey Anderson | HP Inc | 49 | |
Lisa Kastigar | GCM Grosvenor | N/A | |
Kathleen CPA | GCM Grosvenor | N/A | |
Ruairidh Ross | HP Inc | N/A | |
Francesca DeMartino | Pfizer Inc | N/A | |
Moshe Shmaryahu | Nayax | N/A | |
Marie Myers | HP Inc | 56 | |
Luis Cabrera | GCM Grosvenor | N/A | |
Gal Omer | Nayax | 41 | |
Elisabeth Moreno | HP Inc | N/A | |
Andreas Panayiotou | Pfizer Inc | N/A | |
Antonio Lucio | HP Inc | 65 | |
Mikael MD | Pfizer Inc | 66 | |
Sean Conroy | GCM Grosvenor | N/A | |
David Rozzion | HP Inc | N/A | |
Stacie Selinger | GCM Grosvenor | N/A | |
Peter JD | GCM Grosvenor | N/A |
Management Performance
Return On Equity | 0.0887 | ||||
Return On Asset | -0.0497 |
Krystal Biotech Leadership Team
Elected by the shareholders, the Krystal Biotech's board of directors comprises two types of representatives: Krystal Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Krystal. The board's role is to monitor Krystal Biotech's management team and ensure that shareholders' interests are well served. Krystal Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Krystal Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Christine Wilson, Head Marketing | ||
David Chien, Senior Development | ||
Hubert MD, Senior Development | ||
Gloria Lin, Accounting Mang | ||
Kathryn Romano, Executive Officer | ||
Katherine Tuminello, HR Mang | ||
Suma Krishnan, President Founder | ||
Jennifer McDonough, Analytics Access | ||
MS MBA, Chairman, Founder | ||
John Karakkal, Vice Marketing | ||
Ram Kamineni, Senior Operations | ||
David Glynn, Commercial Counsel | ||
John Thomas, General Secretary | ||
Laurent Goux, Senior Europe | ||
Andreas Orth, Ex Officer | ||
Josh Suskin, Director Operations | ||
Meg Dodge, Vice Communications |
Krystal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Krystal Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0887 | ||||
Return On Asset | -0.0497 | ||||
Profit Margin | 0.60 % | ||||
Operating Margin | 0.13 % | ||||
Current Valuation | 4.16 B | ||||
Shares Outstanding | 28.56 M | ||||
Shares Owned By Insiders | 12.75 % | ||||
Shares Owned By Institutions | 94.95 % | ||||
Number Of Shares Shorted | 2.59 M | ||||
Price To Earning | (6.36) X |
Pair Trading with Krystal Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Krystal Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Krystal Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against Krystal Stock
0.59 | INBX | InhibrxInc Earnings Call This Week | PairCorr |
0.57 | SHC | Sotera Health | PairCorr |
The ability to find closely correlated positions to Krystal Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Krystal Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Krystal Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Krystal Biotech to buy it.
The correlation of Krystal Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Krystal Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Krystal Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Krystal Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Krystal Stock analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
CEOs Directory Screen CEOs from public companies around the world | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Krystal Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Krystal Biotech. If investors know Krystal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Krystal Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 2.18 | Revenue Per Share 3.451 | Return On Assets (0.05) | Return On Equity 0.0887 |
The market value of Krystal Biotech is measured differently than its book value, which is the value of Krystal that is recorded on the company's balance sheet. Investors also form their own opinion of Krystal Biotech's value that differs from its market value or its book value, called intrinsic value, which is Krystal Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Krystal Biotech's market value can be influenced by many factors that don't directly affect Krystal Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Krystal Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Krystal Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Krystal Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.